Strategic Direction for Pfizer, Inc. Analytical Essay by Nicky

Looks at the current external and internal environments of Pfizer, Inc. to recommend a strategic direction.
# 150751 | 2,855 words | 9 sources | APA | 2012 | US
Published on Apr 04, 2012 in Business (Companies) , Business (Management) , Medical and Health (Pharmacy)

$19.95 Buy and instantly download this paper now


This paper explains that Pfizer, Inc., one of the five largest worldwide pharmaceutical research-based companies, produces several of the best-selling prescription drugs in the areas of human, animal and consumer (over-the-counter drugs) health care. An analysis of its external environment indicates a threat to the company's intellectual properties; whereas, the author stresses, an internal environment analysis reveals that Pfizer needs to emphasize its open door policy and the potential of becoming a Pfizer supplier. The paper recommends that Pfizer also stress its research initiatives in the areas of discovery and development. This paper contains figures.

Table of Contents:
Current Situation
Key Pharmaceutical Products
Key Animal Products
Corporate Governance
Board of Directors
Top Leadership
External Environment - Opportunities and Threats
Internal Environment - Strength and Weaknesses
Analysis of Strategic Factors
Strategic Alternatives and Recommended Strategy
Evaluation and Control

From the Paper:

"It is reported that Pfizer's 'Powermed: DNA Vaccine Company" is complete with a unique technology platform in which DNA vaccines offer advantages over vaccines that are traditional and cell-based and as well the proprietary technology of PowerMed offers other advantages. PowerMed has the potential for significant revenue and an attractive margin as the Vaccine market is projected for significant growth due to the increased awareness and the desire of consumers for preventive vaccines. As well specialty vaccines command premium pricing. Finally there is a unique opportunity as an entry point for Pfizer's vaccine strategy.
"Threats identified in this study include those in which Pfizer's pharmaceutical have been released for generic duplication by other companies and the fact that those pharmaceuticals will be released into the market and some of which have already been released.
"Pfizer Inc. states that one of the primary limitations of their operations in some countries outside of the United States "is the lack of effective intellectual property protection" for Pfizer Inc. products. Pfizer primary businesses are stated to be conducted in "intensely competitive and often highly regulated markets." Furthermore, most of Pfizer Inc.'s human pharmaceutical products face competition in the form of branded drugs or generic drugs that treat similar diseases or indications.""

Sample of Sources Used:

  • Pfizer Inc (2009) Center for Responsive Politics. Online available at:
  • Pfizer Streamlines Operational Processes to Achieve Balanced Excellence (2004) Tradeline 29 Sept 2004. Online available at;
  • Corporate Governance FactSheet (2009) Pfizer Inc. Online available at:
  • Pfizer's Infectious Disease Commitment and Portfolio (2007) Pfizer, Inc. 18 Sept 2007. Online available at:
  • Pierce, Lisa McTique, Demetrakakes, Pan, and Barry, Christopher (2003) Pfizer's Strategy is a Good Medicine: Drug Packager of the Year - Special: Pfizer Inc." Food and Drugs Packaging 2003 December.

Cite this Analytical Essay:

APA Format

Strategic Direction for Pfizer, Inc. (2012, April 04) Retrieved April 18, 2024, from

MLA Format

"Strategic Direction for Pfizer, Inc." 04 April 2012. Web. 18 April. 2024. <>